---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000021"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2024-01-03T23:59:59+00:00"
generated_at: "2026-06-07T04:34:18.990490+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ProMIS Neurosciences appoints Neil Warma as interim CEO after Gail Farfel departure

## Summary
- CEO Gail Farfel separated as President/CEO and Board member effective Dec 30, 2023; will receive severance per agreement.
- Neil Warma appointed interim CEO effective Dec 30, 2023; continues as Board member.
- Compensation: $250k base salary, up to $400k milestone bonus, and options for 200k shares.
- Warma brings neuroscience background; company plans to advance PMN310 in Alzheimer's and seek partnerships.

## SEC filing metadata
- accession: 0001558370-24-000021
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2024-01-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000155837024000021/0001558370-24-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000155837024000021/pmn-20231230x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000021
- JSON: https://secwatch.observer/filing/0001558370-24-000021.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000021.txt

## Key facts
- Executive change
  Neil Warma was appointed as President and interim Chief Executive Officer at ProMIS Neurosciences Inc..
  - Action: appointed
  - Role: President and interim Chief Executive Officer
  source text: Effective December 30, 2023, the Board appointed Neil Warma as President and interim Chief Executive Officer and principal executive officer of the Company (the “Appointment”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374339/000155837024000021/0001558370-24-000021-index.htm
- Executive change
  Gail Farfel departed as President and Chief Executive Officer at ProMIS Neurosciences Inc..
  - Action: separated
  - Role: President and Chief Executive Officer
  source text: it separated with Gail Farfel, Ph.D. as President and Chief Executive Officer and principal executive officer of the Company, and as a member of the Board of Directors of the Company (the “Board”), in each case, effective as of December 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374339/000155837024000021/0001558370-24-000021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.